The available information is in an Adobe Acrobat PDF format. Please make sure you are using the latest version of Adobe Acrobat Reader. To download Adobe Acrobat Reader, please click on the link below.
- Ultragenyx today announced a Phase 1/2 study of UX003 for MPS VII
- Synageva BioPharma joins the International MPS Network in support of MPS Awareness Day 2013
- Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh To Collaborate On Clinical Studies for Mucopolysaccharidoses
- LYSOGENE received US orphan drug designation for SAF-301 for treatment of MPS III A